Iambic Therapeutics (NASDAQ:IAM – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($6.23) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($5.90), Zacks reports.
Iambic Therapeutics Stock Down 5.3%
Iambic Therapeutics stock traded down $0.70 during mid-day trading on Monday, hitting $12.40. The stock had a trading volume of 62,073 shares, compared to its average volume of 702,201. Iambic Therapeutics has a one year low of $9.60 and a one year high of $25.00.
Insider Buying and Selling
In other Iambic Therapeutics news, Director Evan Lockwood Rachlin acquired 718,750 shares of the stock in a transaction dated Friday, October 16th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the transaction, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. The trade was a 38.45% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Analyst Ratings Changes
Several equities research analysts have recently commented on IAM shares. Zacks Research assumed coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They issued a “hold” rating for the company. Bank of America began coverage on Iambic Therapeutics in a research report on Monday, November 9th. They set a “buy” rating and a $30.00 target price on the stock. Jefferies Financial Group initiated coverage on Iambic Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. began coverage on Iambic Therapeutics in a research report on Monday, November 9th. They issued an “overweight” rating and a $22.00 price target for the company. Finally, Citigroup started coverage on Iambic Therapeutics in a research report on Monday, November 9th. They issued a “buy” rating and a $22.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.25.
Get Our Latest Stock Analysis on Iambic Therapeutics
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
